This recognition underscores ChromaDex's industry-leading NAD+ research and its expanding portfolio of healthy aging products featuring Niagen® (patented nicotinamide riboside or NR), the most efficient and high-quality NAD+ precursor. Such innovative products include the direct-to-consumer dietary supplement, Tru Niagen®, and the newly unveiled pharmaceutical-grade Niagen IV.
Excellence is not about meeting expectations. It is about redefining them. ChromaDex is proud to be honored on Inc. magazine’s 2024 Best in Business List in the Health Products category. Inc. Best in Business celebrates companies that push boundaries and make an indelible mark on the world.
This honor places ChromaDex in extraordinary company. Ossium Health, a leader in stem cell innovation, and Sharebite, a platform revolutionizing food insecurity solutions, exemplify the transformative power of business done right. To join their ranks is an honor that fuels our dedication to advancing cellular health.
At the heart of our innovation lies patented Niagen®, the foundation of Niagen IV. As a leader in healthy-aging cellular science, ChromaDex is pioneering the future of wellness with Niagen IV, now available exclusively through a network of premium clinics across the US.
Designed to deliver advanced intravenous NAD-boosting support, Niagen IV energizes cells, supports the mitochondria, and enhances well-being. Featuring nicotinamide riboside chloride (NRC), the most efficient NAD+ precursor available, Niagen IV boosts NAD+ levels by up to 20% in three hours*, faster than traditional NAD+ IVs**.
“Our mission is to help people around the world to age better, and this honor reflects the progress we’re making toward achieving that goal,” said ChromaDex CEO and Founder of Tru Niagen, Rob Fried.